411 related articles for article (PubMed ID: 29520731)
1. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM; Goey AKL; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2018 Oct; 57(10):1229-1254. PubMed ID: 29520731
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Hahn RZ; Antunes MV; Verza SG; Perassolo MS; Suyenaga ES; Schwartsmann G; Linden R
Curr Med Chem; 2019; 26(12):2085-2107. PubMed ID: 29932028
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and emerging strategies for irinotecan-induced diarrhea.
Xu S; Lan H; Huang C; Ge X; Zhu J
Eur J Pharmacol; 2024 Jul; 974():176614. PubMed ID: 38677535
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.
Liu Z; Martin JH; Liauw W; McLachlan SA; Link E; Matera A; Thompson M; Jefford M; Hicks RJ; Cullinane C; Hatzimihalis A; Campbell I; Crowley S; Beale PJ; Karapetis CS; Price T; Burge ME; Michael M
Eur J Clin Pharmacol; 2022 Jan; 78(1):53-64. PubMed ID: 34480602
[TBL] [Abstract][Full Text] [Related]
5. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
6. Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1
Qin Y; Wang N; Chen F; Han X; Zhu Y; Rang Y; Zhai X; Lu Y
Pharmazie; 2020 May; 75(5):186-190. PubMed ID: 32393425
[TBL] [Abstract][Full Text] [Related]
7. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.
Kümler I; Sørensen PG; Palshof J; Høgdall E; Skovrider-Ruminski W; Theile S; Fullerton A; Nielsen PG; Jensen BV; Nielsen DL
Cancer Chemother Pharmacol; 2019 Jan; 83(1):169-178. PubMed ID: 30406838
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
Paulík A; Nekvindová J; Filip S
Tumori; 2020 Apr; 106(2):87-94. PubMed ID: 30514181
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
11. Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization.
Levy EB; Peer C; Sissung TM; Venkatesan A; Pandalai P; Greten T; Hughes MS; Garcia C; Peretti J; Figg W; Lewis A; Wood B
J Vasc Interv Radiol; 2019 Jan; 30(1):19-22. PubMed ID: 30527657
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Nagar S; Blanchard RL
Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.
Kciuk M; Marciniak B; Kontek R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664667
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.
Riera P; Páez D
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1157-1163. PubMed ID: 34486919
[TBL] [Abstract][Full Text] [Related]
15. High Doses of Δ
Kopjar N; Fuchs N; Brčić Karačonji I; Žunec S; Katić A; Kozina G; Lucić Vrdoljak A
Clin Drug Investig; 2020 Sep; 40(9):775-787. PubMed ID: 32696321
[TBL] [Abstract][Full Text] [Related]
16. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.
Salvador-Martín S; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Pachón V; Longo F; Martínez V; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2018 Oct; 136():133-139. PubMed ID: 30213564
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of irinotecan.
Toffoli G; Cecchin E; Corona G; Boiocchi M
Curr Med Chem Anticancer Agents; 2003 May; 3(3):225-37. PubMed ID: 12769780
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Deeken JF; Slack R; Marshall JL
Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
